新诊断多发性骨髓瘤早期发病率与死亡率的预测因素:来自五项随机对照III期试验3700例患者的数据
该研究分析3700例适合移植的新诊断多发性骨髓瘤患者,接受2005-2020年含新药的三联/四联诱导治疗,识别严重感染/死亡的基线危险因素并建立风险评分,在三个验证队列中独立验证。
要点
- 四个基线危险因素:血小板计数<150/nL、ISS III期、WHO体能状态>1、年龄>60岁,各计1分。
- 风险评分将患者分为低危(0分,39.5%)、中危(1分,41.9%)、高危(≥2分,18.6%)。
- 严重感染/死亡风险低危7.7% vs 中危11.5% vs 高危23.3%(p<0.001)。
核心结论
- 建立了一个稳健且易用的评分,用于识别新诊断多发性骨髓瘤患者严重感染/死亡风险,涵盖最新的四联诱导治疗。
研究设计与样本
- 评估2005-2020年接受含新药三联/四联诱导治疗的3700例适合移植的新诊断多发性骨髓瘤患者。
- 患者分为训练队列(n=1333)和三个验证队列(n=2367)。
- 主要终点为严重感染、死亡或两者组合。
主要发现
- 训练队列中,诱导治疗期间11.8%发生严重感染,1.8%死亡,12.5%发生严重感染和/或死亡。
- 严重感染/死亡风险低危7.7% vs 中危11.5% vs 高危23.3%(p<0.001)。
- 风险评分在三个含抗CD38抗体四联诱导治疗的试验中独立验证。
关键数值与推荐
- 四个主要基线危险因素:血小板计数<150/nL、ISS III期、WHO体能状态>1、年龄>60岁,各计1分。
- 风险评分分层:低危0分(39.5%)、中危1分(41.9%)、高危≥2分(18.6%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Early morbidity and mortality affect patient outcomes in multiple myeloma. Thus, we dissected the incidence and causes of morbidity/mortality during induction therapy (IT) for newly diagnosed multiple myeloma (NDMM), and developed/validated a predictive risk score. We evaluated 3700 transplant-eligible NDMM patients treated in 2005-2020 with novel agent-based triplet/quadruplet IT. Primary endpoints were severe infections, death, or a combination of both. Patients were divided in a training (n = 1333) and three validation cohorts (n = 2367). During IT, 11.8%, 1.8%, and 12.5% of patients in the training cohort experienced severe infections, death, or both, respectively. Four major, baseline risk factors for severe infection/death were identified: low platelet count (<150/nL), ISS III, higher WHO performance status (>1), and age (>60 years). A risk score (1 risk factor=1 point) stratified patients in low (39.5%; 0 points), intermediate (41.9%; 1 point), and high (18.6%; ≥2 points) risk. The risk for severe infection/death increased from 7.7% vs. 11.5% vs. 23.3% in the low- vs. intermediate- vs. high-risk groups (p < 0.001). The risk score was independently validated in three trials incorporating quadruplet IT with an anti-CD38 antibody. Our analyses established a robust and easy-to-use score to identify NDMM patients at risk of severe infection/death, covering the latest quadruplet induction therapies. Trial registrations: HOVON-65/GMMG-HD4: EudraCT No. 2004-000944-26. GMMG-MM5: EudraCT No. 2010-019173-16. GMMG-HD6: NCT02495922. EMN02/HOVON-95: NCT01208766. GMMG-HD7: NCT03617731.
引用
- Mai EK, Hielscher T, Bertsch U, et al. Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients. Leukemia. 2023. PMID: 38062124. doi:10.1038/s41375-023-02105-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。